ALKS vs. NBIX: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ALKS and NBIX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
NBIX’s market capitalization of 12.78 billion USD is significantly greater than ALKS’s 4.76 billion USD, highlighting its more substantial market valuation.
ALKS’s beta of 0.42 points to significantly higher volatility compared to NBIX (beta: 0.24), suggesting ALKS has greater potential for both gains and losses relative to market movements.
| Symbol | ALKS | NBIX |
|---|---|---|
| Company Name | Alkermes plc | Neurocrine Biosciences, Inc. |
| Country | IE | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| CEO | Richard F. Pops | Kyle W. Gano |
| Price | 28.85 USD | 129.11 USD |
| Market Cap | 4.76 billion USD | 12.78 billion USD |
| Beta | 0.42 | 0.24 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | July 16, 1991 | May 23, 1996 |
| ADR | No | No |
Historical Performance
This chart compares the performance of ALKS and NBIX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ALKS
25.41%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
In the upper quartile for the Biotechnology industry, ALKS’s Return on Equity of 25.41% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
NBIX
11.81%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 51.32%
- Q3
- 9.89%
- Median
- -3.37%
- Q1
- -20.99%
- Min
- -36.07%
In the upper quartile for the Drug Manufacturers - Specialty & Generic industry, NBIX’s Return on Equity of 11.81% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Return on Invested Capital
ALKS
20.03%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
In the upper quartile for the Biotechnology industry, ALKS’s Return on Invested Capital of 20.03% signifies a highly effective use of its capital to generate profits when compared to its peers.
NBIX
10.31%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 22.54%
- Q3
- 8.45%
- Median
- 1.42%
- Q1
- -9.01%
- Min
- -28.41%
In the upper quartile for the Drug Manufacturers - Specialty & Generic industry, NBIX’s Return on Invested Capital of 10.31% signifies a highly effective use of its capital to generate profits when compared to its peers.
Net Profit Margin
ALKS
23.30%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
A Net Profit Margin of 23.30% places ALKS in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
NBIX
12.68%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 40.33%
- Q3
- 11.92%
- Median
- -0.45%
- Q1
- -13.07%
- Min
- -34.27%
A Net Profit Margin of 12.68% places NBIX in the upper quartile for the Drug Manufacturers - Specialty & Generic industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin
ALKS
25.84%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
An Operating Profit Margin of 25.84% places ALKS in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
NBIX
20.61%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 46.91%
- Q3
- 19.02%
- Median
- 6.23%
- Q1
- -11.23%
- Min
- -51.89%
An Operating Profit Margin of 20.61% places NBIX in the upper quartile for the Drug Manufacturers - Specialty & Generic industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ALKS | NBIX |
|---|---|---|
| Return on Equity (TTM) | 25.41% | 11.81% |
| Return on Assets (TTM) | 16.94% | 8.29% |
| Return on Invested Capital (TTM) | 20.03% | 10.31% |
| Net Profit Margin (TTM) | 23.30% | 12.68% |
| Operating Profit Margin (TTM) | 25.84% | 20.61% |
| Gross Profit Margin (TTM) | 87.67% | 98.25% |
Financial Strength
Current Ratio
ALKS
3.33
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
ALKS’s Current Ratio of 3.33 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
NBIX
3.13
Drug Manufacturers - Specialty & Generic Industry
- Max
- 5.74
- Q3
- 3.37
- Median
- 2.64
- Q1
- 1.73
- Min
- 0.88
NBIX’s Current Ratio of 3.13 aligns with the median group of the Drug Manufacturers - Specialty & Generic industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
ALKS
0.05
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
ALKS’s Debt-to-Equity Ratio of 0.05 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
NBIX
0.18
Drug Manufacturers - Specialty & Generic Industry
- Max
- 1.45
- Q3
- 1.06
- Median
- 0.62
- Q1
- 0.13
- Min
- 0.00
NBIX’s Debt-to-Equity Ratio of 0.18 is typical for the Drug Manufacturers - Specialty & Generic industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio
ALKS
23.56
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
ALKS’s Interest Coverage Ratio of 23.56 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
NBIX
--
Drug Manufacturers - Specialty & Generic Industry
- Max
- 10.17
- Q3
- 3.39
- Median
- 0.85
- Q1
- -2.63
- Min
- -5.84
Interest Coverage Ratio data for NBIX is currently unavailable.
Financial Strength at a Glance
| Symbol | ALKS | NBIX |
|---|---|---|
| Current Ratio (TTM) | 3.33 | 3.13 |
| Quick Ratio (TTM) | 2.92 | 3.02 |
| Debt-to-Equity Ratio (TTM) | 0.05 | 0.18 |
| Debt-to-Asset Ratio (TTM) | 0.04 | 0.12 |
| Net Debt-to-EBITDA Ratio (TTM) | -0.73 | 0.47 |
| Interest Coverage Ratio (TTM) | 23.56 | -- |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ALKS and NBIX. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ALKS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALKS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
NBIX
0.00%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 9.29%
- Q3
- 0.31%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NBIX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio
ALKS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALKS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
NBIX
0.00%
Drug Manufacturers - Specialty & Generic Industry
- Max
- 125.42%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NBIX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ALKS | NBIX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio
ALKS
13.37
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
ALKS’s P/E Ratio of 13.37 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
NBIX
42.09
Drug Manufacturers - Specialty & Generic Industry
- Max
- 40.89
- Q3
- 28.12
- Median
- 23.94
- Q1
- 18.79
- Min
- 7.76
At 42.09, NBIX’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Drug Manufacturers - Specialty & Generic industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
Forward P/E to Growth Ratio
ALKS
3.18
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
ALKS’s Forward PEG Ratio of 3.18 is exceptionally high for the Biotechnology industry. This suggests its stock price is very high relative to its expected earnings growth, signaling significant overvaluation risk.
NBIX
1.48
Drug Manufacturers - Specialty & Generic Industry
- Max
- 4.19
- Q3
- 2.94
- Median
- 1.47
- Q1
- 0.35
- Min
- 0.00
NBIX’s Forward PEG Ratio of 1.48 is within the middle range of its peers in the Drug Manufacturers - Specialty & Generic industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
Price-to-Sales Ratio
ALKS
3.14
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
In the lower quartile for the Biotechnology industry, ALKS’s P/S Ratio of 3.14 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
NBIX
5.30
Drug Manufacturers - Specialty & Generic Industry
- Max
- 7.49
- Q3
- 4.45
- Median
- 2.12
- Q1
- 1.21
- Min
- 0.25
NBIX’s P/S Ratio of 5.30 is in the upper echelon for the Drug Manufacturers - Specialty & Generic industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio
ALKS
3.12
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
NBIX
5.08
Drug Manufacturers - Specialty & Generic Industry
- Max
- 4.93
- Q3
- 3.95
- Median
- 2.14
- Q1
- 1.30
- Min
- 0.13
The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - Specialty & Generic industry.
Valuation at a Glance
| Symbol | ALKS | NBIX |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 13.37 | 42.09 |
| Forward PEG Ratio (TTM) | 3.18 | 1.48 |
| Price-to-Sales Ratio (P/S, TTM) | 3.14 | 5.30 |
| Price-to-Book Ratio (P/B, TTM) | 3.12 | 5.08 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 9.88 | 25.96 |
| EV-to-EBITDA (TTM) | 9.90 | 24.14 |
| EV-to-Sales (TTM) | 2.93 | 5.40 |